Craft

Genexine

Stock Price

₩6.3 K

2024-07-03

Market Capitalization

₩262.8 B

2024-07-03

Revenue

₩16.1 B

FY, 2022

Genexine Summary

Company Summary

Overview
Genexine is a biotechnology company focused on the development and commercialization of immunotherapeutics and long-acting biologics. It builds the hyFc technology, a proprietary platform designed to drive the discovery of differentiated protein therapeutics.
Type
Public
Status
Active
Founded
1999
HQ
Seongnam-si, KR | view all locations
Website
http://www.genexine.com
Cybersecurity rating
ESG rating
30-39 out of 100|View all ESG data
Sectors

LocationsView all

2 locations detected

  • Seongnam-si, Gyeonggi-do HQ

    Korea (Republic of)

  • New York, NY

    United States

    Lefcourt Colonial Building, 295 Madison Ave #1201

Genexine Financials

Summary Financials

Revenue (Q3, 2023)
₩368.5M
Gross profit (Q3, 2023)
₩2.6B
Net income (Q3, 2023)
(₩20.9B)
Cash (Q3, 2023)
₩2.5B
EBIT (Q3, 2023)
(₩21.4B)
Enterprise value
$341.1B

Footer menu